AU2001251595A1 - Gaba substrate and the use thereof for treating cognitive and emotional disorders - Google Patents

Gaba substrate and the use thereof for treating cognitive and emotional disorders

Info

Publication number
AU2001251595A1
AU2001251595A1 AU2001251595A AU5159501A AU2001251595A1 AU 2001251595 A1 AU2001251595 A1 AU 2001251595A1 AU 2001251595 A AU2001251595 A AU 2001251595A AU 5159501 A AU5159501 A AU 5159501A AU 2001251595 A1 AU2001251595 A1 AU 2001251595A1
Authority
AU
Australia
Prior art keywords
treating cognitive
emotional disorders
gaba
substrate
gaba substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251595A
Inventor
William T Evans
Dwight L. Mckee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001251595A1 publication Critical patent/AU2001251595A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
AU2001251595A 2000-04-13 2001-04-12 Gaba substrate and the use thereof for treating cognitive and emotional disorders Abandoned AU2001251595A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19681300P 2000-04-13 2000-04-13
US60196813 2000-04-13
PCT/US2001/012076 WO2001078704A2 (en) 2000-04-13 2001-04-12 Gaba substrate and the use thereof for treating cognitive and emotional disorders

Publications (1)

Publication Number Publication Date
AU2001251595A1 true AU2001251595A1 (en) 2001-10-30

Family

ID=22726886

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251595A Abandoned AU2001251595A1 (en) 2000-04-13 2001-04-12 Gaba substrate and the use thereof for treating cognitive and emotional disorders

Country Status (3)

Country Link
US (1) US6498247B2 (en)
AU (1) AU2001251595A1 (en)
WO (1) WO2001078704A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142859A1 (en) * 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
DE10149108A1 (en) * 2001-10-05 2003-04-30 Degussa Bioactives Deutschland Use of phosphatidylserine to treat Attention Deficit Disorder (ADHD)
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6713497B1 (en) * 2003-03-17 2004-03-30 Brookhaven Science Associates, Llc Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7718416B1 (en) 2005-04-02 2010-05-18 Nse Products, Inc. Fungal-derived formulations and associated methods
US8142803B2 (en) * 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
EP2139466B1 (en) * 2007-03-22 2019-10-23 Neurocentria, Inc. Magnesium compositions and uses thereof
US8377473B2 (en) * 2009-07-01 2013-02-19 Magceutics, Inc. Slow release magnesium composition and uses thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
EP2974731A1 (en) * 2014-07-18 2016-01-20 Hennig Arzneimittel GmbH&Co. Kg Administration form containing fungal components
WO2016167944A2 (en) * 2015-04-14 2016-10-20 Steve Hoffman Compositions and methods for treating intestinal hyperpermeability
US20180353447A1 (en) * 2015-11-27 2018-12-13 Birrbeheer B.V. Butyrate salts for use in inflammatory diseases
ES2914650T3 (en) * 2016-04-27 2022-06-15 Abergavenny Nv choline butyrate salt
CN107875198A (en) * 2017-11-16 2018-04-06 广西***华春福家庭农场 A kind of Chinese medicine composition for treating syphilis and preparation method thereof
WO2019147892A1 (en) * 2018-01-27 2019-08-01 Ben Tre Gay B Formulation for the treatment of polymorphisms in methyl metabolizing genes and methods of treatment thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721716A (en) * 1984-08-06 1988-01-26 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
KR910000102A (en) 1988-06-02 1991-01-29 유다까 미시마 Enzyme inhibitor
JP3971454B2 (en) 1993-10-29 2007-09-05 ザ トラスティーズ オブ ボストン ユニバーシティ Physiologically stable compositions of butyric acid, butyrate, and derivatives as anti-neoplastic agents
US5563173A (en) 1994-12-22 1996-10-08 Research Development Foundation Anti-proliferative effects of sodium butyrate
FI951778A (en) * 1995-04-12 1996-10-13 Aboatech Ab Oy Method for diagnosing allergies
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
US6316690B1 (en) * 1999-08-04 2001-11-13 Tosk, Inc. Non-mammalian transgenic animal model for cellular proliferative diseases

Also Published As

Publication number Publication date
WO2001078704A2 (en) 2001-10-25
WO2001078704A3 (en) 2002-02-07
US6498247B2 (en) 2002-12-24
US20020048612A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
AU2001251595A1 (en) Gaba substrate and the use thereof for treating cognitive and emotional disorders
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2001293745A1 (en) Device and method for the surface treatment of workpieces
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2001229075A1 (en) Self-alignment hybridization process and component
AU6910600A (en) Methods for the treatment of mental disorders
AU2001287141A1 (en) Semiconductor device and process for forming the same
AU3086900A (en) Device for the complex treatment of disorders of the prostate
AU2002366436A1 (en) Water filters and processes for using the same
AU5838700A (en) Method for treating and preventing finger disorders
WO2003039490A9 (en) Compositions and methods for diagnosing and treating mental disorders
AU2001293891A1 (en) New combination for the treatment of asthma
AU2002367087A1 (en) Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
EP1277860B8 (en) Apparatus for manufacturing effect yarns and the use thereof
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU2002320630A1 (en) Detecting and treating reproductive tract disorders
AU5855899A (en) Method for identifying substances for the treatment of c-jun-mediated disorders
AU2002229905A1 (en) Copper-cerium adsorbent and desulphurization process using the same
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
PL354111A1 (en) Combined therapy for treating the both depression and anxiety